Enliven Therapeutics, Inc. Common Stock
Here’s whether Enliven Therapeutics, Inc. Common Stock (ELVN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.18% over 10 days); RSI 60 — healthy momentum range; strong 1-year return of +134.6%; 3-month momentum positive (+68.4%); rising volume confirms the move (1.86x 30d avg). Currently 5.0% off its 52-week high. Score: +8/7.
ELVN is in a confirmed uptrend, trading above both its 50-day ($41.53) and 200-day ($27.77) moving averages. An RSI of 59.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +134.6% compares to +22.9% for SPY (beat the market by 111.8%).